Chembio Diagnostic Systems, Inc.
http://chembio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Chembio Diagnostic Systems, Inc.
FDA Pulls Chembio’s Rapid Test As Purge Of ‘Inaccurate’ Antibody Tests Continues
Chembio’s stock opened down 60% the day after the FDA’s decision to revoke its EUA for the first US rapid test for antibodies to SARS-CoV-2.
COVID-19: FDA Warns Of Potential Risks Of Antibody Tests
The US agency’s decision to allow developers to distribute tests that detect COVID-19 in human blood without going through a clearance process has led to some misleading marketing, the agency warned in two recent statements.
Dravet Syndrome: A Rare Epilepsy, Now With Two Approved Treatments
Biocodex's Diacomit – long approved in the EU – just won FDA approval. That brings the number of drugs cleared for Dravet in the US to two, including GW Pharma's recently endorsed Epidiolex, and the R&D pipeline for this rare seizure disorder is growing.
Deals Shaping the Medical Industry, January 2018
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.
Company Information
- Industry
- Biotechnology
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
-
Diagnostic Imaging Equipment & Supplies
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Other Names / Subsidiaries
-
- RVR Diagnostics Sdn Bhd (RVR)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice